Home › Funds › ACORN CAPITAL ADVISORS, LLC › CADL
ACORN CAPITAL ADVISORS, LLC position in CADL
CANDEL THERAPEUTICS INC · Health Care
ACORN CAPITAL ADVISORS, LLC reported holding 3,497,948 shares of CADL (CANDEL THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$36.5M, representing 10.03% of its reported portfolio and ranking #4 among its reported holdings. ACORN CAPITAL ADVISORS, LLC has disclosed CADL holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How ACORN CAPITAL ADVISORS, LLC's CADL position evolved
ACORN CAPITAL ADVISORS, LLC first disclosed a stake in CADL in Q4 2024 at 1,939,644 shares (US$16.8M). The position peaked in Q3 2026 at 3,497,948 shares, worth US$36.5M. Across 8 filings, ACORN CAPITAL ADVISORS, LLC increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 3,497,948 shares valued at US$36.5M. Notable position changes include a 36% increase in Q1 2026 (shares rose 110% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 1.94M | $16.84M | New |
| Q1 2025 | 2.15M | $12.16M | Add |
| Q2 2025 | 2.58M | $13.06M | Add |
| Q3 2025 | 2.58M | $13.16M | Hold |
| Q4 2025 | 2.58M | $14.58M | Hold |
| Q1 2026 | 3.50M | $17.21M | Add |
| Q2 2026 | 3.50M | $36.03M | Hold |
| Q3 2026 | 3.50M | $36.52M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CADL and 13F data
CADL (CANDEL THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in CADL — the largest reported positions include Saturn V Capital Management LP (US$36.3M), Portolan Capital Management, LLC (US$36.0M), Sands Capital Alternatives, LLC (US$4.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CADL
- Saturn V Capital Management LP 3.48M sh · $36.29M · Q3 2026
- Portolan Capital Management, LLC 3.49M sh · $35.95M · Q2 2026
- Sands Capital Alternatives, LLC 405.84K sh · $4.24M · Q3 2026
- Tanager Wealth Management LLP 198.18K sh · $2.07M · Q3 2026
- ACT Capital Partners, L.P. 150.50K sh · $1.57M · Q3 2026
More on ACORN CAPITAL ADVISORS, LLC
FAQ
How long has ACORN CAPITAL ADVISORS, LLC held CADL?
ACORN CAPITAL ADVISORS, LLC has disclosed CADL holdings in 8 of the last 8 reported quarters, going back to Q4 2024.
What is ACORN CAPITAL ADVISORS, LLC's current position in CADL?
As of Q3 2026, ACORN CAPITAL ADVISORS, LLC holds 3.50M shares of CADL (CANDEL THERAPEUTICS INC), valued at $36.52M, representing 10.03% of its reported portfolio and ranking #4.
Has ACORN CAPITAL ADVISORS, LLC been buying or selling CADL?
In the latest 13F filing (Q3 2026), ACORN CAPITAL ADVISORS, LLC held unchanged its position in CADL. The position peaked in Q3 2026 at 3.50M shares.
Which other funds hold CADL?
Other major institutional holders of CADL include Saturn V Capital Management LP, Portolan Capital Management, LLC, Sands Capital Alternatives, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.